{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:12:14Z","timestamp":1769227934903,"version":"3.49.0"},"reference-count":0,"publisher":"Aging and Disease","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["aging dis"],"abstract":"<jats:p>The measurement of fluid biomarkers such as phosphorylated tau at threonine 181 (pTAU181), amyloid-\u03b2 40 (A\u03b240), and A\u03b242 is a routine medical examination that contributes to achieving an accurate diagnosis within the Alzheimer\u2019s disease (AD) clinical continuum. The aim of this study is to compare the concentration of these biomarkers in CSF and plasma and determine their relationship with the patients\u2019 clinical variant and profile. Patients were diagnosed following the NIA-AA criteria. Plasma and CSF were obtained from healthy controls (HC), mild cognitive impairment (MCI non-AD), MCI displaying positive AD markers (MCI-AD), and AD patients. Biomarker levels were assessed using the LUMIPULSE\u00ae G600II instrument (Fujirebio, Japan). Data showed a significant increase in pTAU181 concentration, specifically in the progression from MCI non-AD to AD conditions. The opposite trend was observed for A\u03b242 and A\u03b242\/A\u03b240. Furthermore, these biomarker trends appeared to change consistently with variations in the MMSE score, highlighting the relevance of plasma in detecting changes in patients\u2019 cognitive function. Considering the clinical variant, atypical patients displayed the highest pTAU181 and lowest A\u03b242 levels, consistent with their lower MMSE scores. Lastly, the posterior cortical atrophy (PCA) profile showed higher pTAU181 and lower A\u03b242 levels when compared to other profiles. Nevertheless, these last results are to be cautiously interpreted given the limited number of samples included in the analysis. Hence, further analyses on larger cohorts are needed to better define the role of these biomarkers in distinguishing between patients\u2019 clinical variants.<\/jats:p>","DOI":"10.14336\/ad.2025.0971","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:25:11Z","timestamp":1769131511000},"source":"Crossref","is-referenced-by-count":0,"title":["Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients\u2019 Phenotype and Profile"],"prefix":"10.14336","member":"5462","published-online":{"date-parts":[[2026]]},"container-title":["aging and disease"],"original-title":[],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:25:11Z","timestamp":1769131511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2025.0971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":0,"URL":"https:\/\/doi.org\/10.14336\/ad.2025.0971","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}